Novo Nordisk – The Milli Chronicle

Monday, January 5, 2026

Latest:

Maduro Faces U.S. Drug Charges in New York as Venezuela Adjusts to Power Shock
Russia Reassesses Global Strategy After Losing Venezuela Ally Amid U.S. Power Play
Iran’s Leadership Faces Mounting Pressure as Protests Intensify and U.S. Actions Abroad Raise Alarm
Switzerland Freezes Assets Linked to Venezuela’s Maduro as International Pressure Mounts
Bird Flu Outbreaks Raise Fresh Poultry and Public Health Concerns in Southern India

Factual Version of a Story

NewsDesk Milli Chronicle January 5, 2026 chronic obesity treatment, FDA approved weight loss pill, global pharma industry, healthcare accessibility, medical weight loss, metabolic health, needle free treatment, Novo Nordisk, obesity care, obesity treatment, oral weight loss medication, patient centered care, pharmaceutical innovation, self pay patients, semaglutide, telehealth pharmacy, US healthcare market, Wegovy pill, weight loss drug, weight management

Novo Nordisk Expands Weight-Loss Treatment Options with US Launch of Wegovy Oral Pill

The launch of Wegovy in pill form marks a major step in widening access to obesity treatment in the United

Featured News World

NewsDesk Milli Chronicle November 13, 2025November 13, 2025 digital health, drug partnership denial, drug safety, Eli Lilly, Eli Lilly news, fake weight-loss drugs, GLP-1 treatments, healthcare transparency, Mangoceuticals, Mounjaro, Novo Nordisk, Novo Nordisk news, obesity drug market, obesity drugs, obesity treatment market, online pharmacy safety, pharmaceutical industry, telehealth company, telemedicine, Wegovy, weight loss medication, Zepbound

Novo Nordisk and Eli Lilly Reject Claims of Partnership with Mangoceuticals on Obesity Drugs

Novo Nordisk and Eli Lilly clarify that they have no collaboration or special arrangement with telehealth firm Mangoceuticals, following misleading

Asia Latest News

NewsDesk Milli Chronicle November 7, 2025 active pharmaceutical ingredients, API demand, API exports, API manufacturing, API production growth., biotechnology India, CDMO services, contract manufacturing, diabetes drugs, Divi’s Laboratories, Divi’s profits, drug manufacturing, Eli Lilly, European pharma, global healthcare, global pharma supply chain, Hyderabad pharma company, India drugmakers, Indian pharmaceutical exports, Novo Nordisk, pharma growth India, pharma industry trends, pharma investment, pharmaceutical innovation, pharmaceutical R&D, sustainable manufacturing, US market pharma, weight-loss drugs

Divi’s Laboratories Reports Strong Q2 Growth, Driven by Rising API Demand and Global Expansion

Hyderabad – Indian pharmaceutical giant Divi’s Laboratories outperforms expectations with a surge in profits and strong export performance amid growing

Asia Latest News

NewsDesk Milli Chronicle November 7, 2025November 7, 2025 Cipla, diabetes care India, diabetes control, diabetes treatment India, Eli Lilly, Eli Lilly India, GLP-1 drugs, healthcare growth India, healthcare technology, Hyderabad health innovation, India pharma market, medical innovation, metabolic health, Mounjaro, Novo Nordisk, obesity awareness, obesity treatment, pharmaceutical sales India, Wegovy, weight management therapy, weight-loss drug India, weight-loss injection

Eli Lilly’s Mounjaro Becomes India’s Top-Selling Drug, Signaling a New Era in Healthcare Innovation

Hyderabad – Eli Lilly’s groundbreaking weight-loss and diabetes treatment, Mounjaro, takes the top spot in India’s pharmaceutical market, marking a

Featured News World

NewsDesk Milli Chronicle November 6, 2025November 6, 2025 affordable healthcare, American health programs, diabetes care, drug pricing reform, Eli Lilly, GLP-1 medications, healthcare accessibility, injectable treatments, Medicaid access, Medicaid benefits, medical affordability, Medicare coverage, Medicare discounts, Novo Nordisk, obesity treatment, orforglipron, pharmaceutical innovation, prescription savings, public-private partnership, Trump health deal, TrumpRx program, U.S. drug market, U.S. healthcare reform, Wegovy, weight-loss drugs, weight-loss pills, Zepbound

U.S. Strikes Breakthrough Deal to Boost Access to Weight-Loss Drugs

A landmark public-private partnership aims to make life-changing obesity and diabetes treatments more affordable and accessible for millions across America.

Pfizer Strengthens Its Bid for Metsera, Reinforces Commitment to Innovation in Obesity Treatment

Pfizer’s strategic move to revise its bid for Metsera underscores its dedication to advancing next-generation obesity therapies and fostering competition

Featured News World

NewsDesk Milli Chronicle November 2, 2025 biopharma strategy, corporate restructuring, denmark, diabetes treatment, Eli Lilly, global healthcare market, global operations, global restructuring, healthcare industry, healthcare leadership, job cuts, Kalundborg facility, Mike Doustdar, Novo Nordisk, Novo Nordisk future plans., obesity drugs, pharmaceutical innovation, research and development, sustainable growth, workforce transformation

Novo Nordisk Nears Completion of Global Restructuring, Poised for Stronger Growth Ahead

Novo Nordisk’s global transformation plan, including the restructuring of its workforce, is nearly complete, signaling the company’s focus on innovation,

Featured News World